4-氯-7-氮杂吲哚-5-甲醛 | 958230-19-8

• 物质功能分类: 医药中间体 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-氯-7-氮杂吲哚-5-甲醛
• 中文别名: 4-氯-1H-吡咯[2,3-b]吡啶-5-甲醛；4-氯-5-甲酰基-7-氮杂吲哚；4-氯-5-甲醛氮杂吲哚
• 英文名称: 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde
• CAS: 958230-19-8
• 化学式: C₈H₅ClN₂O
• mdl: MFCD09859124
• 分子量: 180.593
• InChiKey: SVRMXFJXIGCKII-UHFFFAOYSA-N

物化性质

• 密度：
  1.521±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26
• 危险类别码：
  R36
• 海关编码：
  2933990090
• 危险标志：
  GHS07
• 危险性描述：
  H302,H319
• 危险性防范说明：
  P305 + P351 + P338
• 储存条件：
  应存放在室温、干燥且密封的环境中。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Chloro-1H-Pyrrolo[2,3-B]Pyridine-5-Carbaldehyde
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H319 Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 180,6 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Chloro-1H-Pyrrolo[2,3-B]Pyridine-5-Carbaldehyde
Acute Tox. 4; Eye Irrit. 2; <= 100 %
H302, H319
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Chloro-1H-Pyrrolo[2,3-B]Pyridine-5-Carbaldehyde
Xn, R22R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Irrit. Eye irritation
H302 Harmful if swallowed.
H319 Causes serious eye irritation.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
R36 Irritating to eyes.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

4-氯-7-氮杂吲哚-5-甲醛可用作有机合成中间体和医药中间体，主要应用于实验室研发及医药化工生产过程。

反应信息

• 作为反应物：
  描述：

  4-氯-7-氮杂吲哚-5-甲醛 在 四丁基氟化铵 、 sodium hydride 、 (1S)-(+)-10-camphorsulfonic acid 、 溶剂黄146 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 5,5-dimethyl-1,3-cyclohexadiene 、 二氯甲烷 、 乙二醇甲醚 、 水 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 64.5h， 生成 培米加替尼
  参考文献：
  名称：

  发现 Pemigatinib：一种有效且选择性的成纤维细胞生长因子受体 (FGFR) 抑制剂

  摘要：

  FGFR 的异常激活与许多肿瘤类型的发病机制有关。FGFR 的选择性抑制已成为一种有前途的癌症治疗方法。在此，我们描述了化合物38（INCB054828，pemigatinib）的发现，该化合物是 FGFR1、FGFR2 和 FGFR3 的高效选择性抑制剂，具有优异的理化特性和药代动力学特征。Pemigatinib 已获得美国食品和药物管理局的加速批准，用于治疗患有 FGFR2 融合或其他重排的先前治疗过的、不可切除的局部晚期或转移性胆管癌的成人。其他临床试验正在进行中，以在 FGFR 改变的患者中评估 pemigatinib。

  DOI：

  10.1021/acs.jmedchem.1c00713
• 作为产物：
  描述：

  4-氯-1-[三(甲基乙基)硅酯]-1H-吡咯并[2,3-B]吡啶 以88的产率得到4-氯-7-氮杂吲哚-5-甲醛
  参考文献：
  名称：

  新的三环化合物

  摘要：

  本发明提供如本文中定义的式(Ia)、(Ib)、(Ic)、(Id)、(Ie)、(If)、(Ig)、(Ih)、(Ii)、(Ij)、(Ik)或(Il)的化合物，其药学可接受的盐、前药、生物活性代谢物、立体异构体和异构体，其中变量是在本文中限定的。本发明化合物可用于治疗免疫和肿瘤状况。

  公开号：

  CN102711470A

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• [EN] OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES AS MAGL INHIBITORS<br/>[FR] OCTAHYDROPYRIDO[1,2-ALPHA]PYRAZINES EN TANT QU'INHIBITEURS DE MAGL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019134985A1

  公开（公告）日：2019-07-11

  The invention provides new heterocyclic compounds having the general formula (le), wherein R1, R1a and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds. The compounds of formula (le) are monoacylglycerol lipase (MAGL) inhibitors, for use in the treatment of a variety of disorders.

  这项发明提供了具有一般式（Ie）的新杂环化合物，其中R1、R1a和R7如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。式（Ie）的化合物是单酰基甘油酶（MAGL）抑制剂，用于治疗各种疾病。
• [EN] NOVEL TRICYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES
  申请人：ABBOTT LAB

  公开号：WO2011068899A1

  公开（公告）日：2011-06-09

  The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了本公式(Ia)、(Ib)、(Ic)、(Id)、(Ie)、(If)、(Ig)、(Ih)、(Ii)、(Ij)、(Ik)或(Il)的化合物，以及在此定义的药学上可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤病症有用。
• DERIVATIVES OF AN FGFR INHIBITOR
  申请人：Incyte Corporation

  公开号：US20210171522A1

  公开（公告）日：2021-06-10

  The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

  本公开涉及一种成纤维细胞生长因子受体（FGFR）抑制剂的衍生物（例如，羟基，酮基，葡萄糖醛酸盐，磺酸盐和氘代物），包括其制备方法以及在制备过程中有用的中间体，这些衍生物在治疗FGFR介导的疾病如癌症方面是有用的。
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS
  申请人：Ren Pingda

  公开号：US20100048552A1

  公开（公告）日：2010-02-25

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

  本发明提供了一类新型化合物，包括含有这种化合物的药物组合物以及使用这种化合物治疗或预防与异常或非正常激酶活性相关的疾病或失调的方法，特别是那些涉及到Abl、Bcr-Abl、Bcr-Abl(T315I)、ALK、BLK、BMX、BRK、C-kit、c-RAF、CSK、c-SRC、EGFR、Fes、FGFR3、Flt3、Fms、Fyn、IGF-1R、IR、JAK(2)、JAK(3)、KDR、Lck、NLK、p70S6K、PDGFRα、Ros、SAPK2α、SGK、SIK、Syk、Tie2和TrkB激酶的异常激活的疾病或失调。